S&P 500
(-1.46%) 5 123.41 points
Dow Jones
(-1.24%) 37 983 points
Nasdaq
(-1.62%) 16 175 points
Oil
(0.51%) $85.45
Gas
(0.51%) $1.773
Gold
(-0.53%) $2 360.20
Silver
(-0.99%) $27.97
Platinum
(0.18%) $989.80
USD/EUR
(0.79%) $0.939
USD/NOK
(0.59%) $10.89
USD/GBP
(0.83%) $0.803
USD/RUB
(0.01%) $93.28

Realtime updates for BioNTech SE [BNTX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
61.29%
return -4.70%
SELL
36.67%
return 4.60%

Live Chart Being Loaded With Signals

Commentary ():

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer...

Stats
Today's Volume 0
Average Volume 0
Market Cap 0
EPS €0 ( 2024-03-20 )
Next earnings date ( €-0.690 ) 2024-05-06
Last Dividend €2.11 ( 2022-06-02 )
Next Dividend €0 ( N/A )
P/E 0
ATR14 €0 (0.00%)

BioNTech SE Correlation

10 Most Positive Correlations
VERB0.95
OPINL0.946
BNGO0.944
VRAY0.944
AUDC0.942
NESR0.939
EGBN0.939
CNXC0.938
MAGS0.938
AGIL0.938
10 Most Negative Correlations
XPDB-0.94
ITAQ-0.939
SWAV-0.937
ROCL-0.935
ATEC-0.934
FTPA-0.932
TIOA-0.931
ROC-0.931
CBRG-0.93
BRIVU-0.929

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioNTech SE Financials

Annual 2023
Revenue: €3.82B
Gross Profit: €3.22B (84.29 %)
EPS: €3.79
Q4 2023
Revenue: €1.48B
Gross Profit: €1.30B (87.89 %)
EPS: €1.880
Q3 2023
Revenue: €895.30M
Gross Profit: €235.60M (26.32 %)
EPS: €0.690
Q2 2023
Revenue: €167.70M
Gross Profit: €-368.60M (-219.80 %)
EPS: €-0.790

Financial Reports:

No articles found.

BioNTech SE Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

BioNTech SE Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.73 - good (97.30%) | Divividend Growth Potential Score: 2.39 - No dividend growth expected in the near future
Information
First Dividend €2.11 2022-06-02
Last Dividend €2.11 2022-06-02
Next Dividend €0 N/A
Payout Date 2022-06-17
Next Payout Date N/A
# dividends 1 --
Total Paid Out €2.11 --
Avg. Dividend % Per Year 0.15% --
Score 1.89 --
Div. Sustainability Score 9.73
Div.Growth Potential Score 2.39
Div. Directional Score 6.06 --
Next Divdend (Est)
(2024-04-13)
€0 Estimate 0.00 %
Dividend Stability
0.04 Very Bad
Dividend Score
1.89
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2022 €2.11 0.91%
2023 €0 0.00%
2024 €0 0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2441.5005.137.69[0 - 0.5]
returnOnAssetsTTM0.04041.2008.6510.00[0 - 0.3]
returnOnEquityTTM0.04641.500-0.596-0.894[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM9.430.80010.008.00[1 - 3]
quickRatioTTM9.120.80010.008.00[0.8 - 2.5]
cashRatioTTM5.631.50010.0010.00[0.2 - 2]
debtRatioTTM0.00952-1.5009.84-10.00[0 - 0.6]
interestCoverageTTM5.581.0009.049.04[3 - 30]
operatingCashFlowPerShareTTM22.592.002.474.94[0 - 30]
freeCashFlowPerShareTTM19.632.000.1860.373[0 - 20]
debtEquityRatioTTM0.0108-1.5009.96-10.00[0 - 2.5]
grossProfitMarginTTM0.5271.0004.544.54[0.2 - 0.8]
operatingProfitMarginTTM0.1811.0008.388.38[0.1 - 0.6]
cashFlowToDebtRatioTTM24.521.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.1660.800-2.23-1.781[0.5 - 2]
Total Score9.73

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM21.081.0007.970[1 - 100]
returnOnEquityTTM0.04642.50-0.383-0.894[0.1 - 1.5]
freeCashFlowPerShareTTM19.632.003.460.373[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM22.592.002.474.94[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM01.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM1.4061.00010.000[0.1 - 0.5]
Total Score2.39

BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators